Research programme: parathyroid hormone antagonists - Xoma

Drug Profile

Research programme: parathyroid hormone antagonists - Xoma

Alternative Names: Anti-PTH1R antibodies - Xoma

Latest Information Update: 25 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator XOMA
  • Class Monoclonal antibodies
  • Mechanism of Action Parathyroid hormone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Malignant hypercalcaemia; Primary hyperparathyroidism

Most Recent Events

  • 08 Nov 2016 Research programme: parathyroid hormone antagonists - Xoma is available for licensing as of 08 Nov 2016. http://www.xoma.com/content/pipeline/research-programs.htm
  • 08 Nov 2016 Preclinical trials in Hyperparathyroidism in USA (Parenteral)
  • 08 Nov 2016 Preclinical trials in Malignant hypercalcaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top